CD274 and skin squamous cell carcinoma: We could not perform immunohistochemistry test for PD-L1 due to financial restrains, but this did not hinder initiation of immunotherapy as the benefit from pembrolizumab in cSCC was observed regardless of PD-L1 combined positive score (CPS) (24).